Post on 06-Jan-2016
description
Trial profile
Mann JF et al. Lancet 2008;372:547-53
Decrease in estimated glomerular filtration rate (eGFR) during the trial, from baseline to study end
Mann JF et al. Lancet 2008;372:547-53
Estimated glomerular filtration rate at baseline and changes of eGFR
Mann JF et al. Lancet 2008;372:547-53
Incidence of primary and secondary renal outcomes and of its components
Mann JF et al. Lancet 2008;372:547-53
Kaplan-Meier curves for (A) primary renal outcome (dialysis, doubling of serum
creatinine, anddeath), (B) secondary
renal outcome (dialysis and doubling of
serum creatinine), and (C) dialysis
T=telmisartanR=ramipril
Mann JF et al. Lancet 2008;372:547-53
Relative risk for primary renal outcome in subgroups (A) Comparison of ramipril and telmisartanThe interaction term tests whether there is an interaction
of the subgroup with the two treatment modalities
Mann JF et al. Lancet 2008;372:547-53
Relative risk for primary renal outcome in subgroups (B) Comparison of ramipril and telmisartan plus ramipril
The interaction term tests whether there is an interaction of the subgroup with the two treatment modalities
Mann JF et al. Lancet 2008;372:547-53
Changes in log urine albumin to creatinine ratio
Mann JF et al. Lancet 2008;372:547-53